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OSTEOPOROSIS DIAGNOSIS AND TREATMENT
Márcio Passini Gonçalves de Souza
ABSTRACT
Articles that update the state of knowledge regarding osteoporosis run the risk of quickly becoming obsolete because research 
and studies on osteoporosis today are arousing great interest among researchers, the pharmaceutical and medical equipment 
industries, governments and even WHO. All orthopedists know about osteoporosis because of its most deleterious effect: os-
teoporotic fracture. Osteoporosis without fractures does not arouse suspicion because this is a pathological condition with a 
nonspecific clinical profile. Osteoporotic fractures have an economic cost (from treatment), a social cost (from its sequelae) 
and a medical cost (from deaths). Many fractures could be avoided through diagnosing osteoporosis prior to the first fracture 
and thus many temporary and permanent disabilities could be avoided and many lives saved. Awareness of the risk factors for 
osteoporosis raises suspicions and bone densitometry aids in diagnosis. Treatment should be based on the physiopathology of 
the disease. Hence, for prevention or treatment of osteoporosis, the activity of osteoclasts should be diminished or the activity of 
osteoblasts should be increased, or both. Treatment that reduces the incidence of fractures by improving the bone geometry and 
microarchitecture would be ideal. Newly formed bone tissue needs to have good cell and matrix quality, normal mineralization, 
a good ratio between mineralized (mechanically resistant) and non-mineralized (flexible) bone, and no accumulated damage. 
The ideal treatment should have a positive remodeling rate and fast and long-lasting therapeutic effects. Such effects need to be 
easily detectable. They need to be safe.
Keywords – Osteoporosis/physiopathology; Osteoporosis/diagnosis; Osteoporosis/prevention & control; Bone fractures.
INTRODUCTION
For many years, studies on osteoporosis were rel-
egated to the back burner because this knowledge had 
little practical value. Today, as well as being a subject 
greatly researched around the world, knowledge of os-
teoporosis is objective and useful. Articles that provide 
updates on this topic rapidly become obsolete because 
the knowledge on this subject is constantly evolving.
Basic knowledge about osteoporosis has been im-
printed in orthopedists’ awareness ever since the start 
of the twentieth century. The word osteoporosis arose 
from a histological study on an osteoporotic bone by Jean 
Georges Chretien Frederic Martin Lobstein, a French 
pathologist, in 1830 apud Oliveira(1), but it became popu-
larized among orthopedists as a radiological sign that sig-
nified bone rarefaction in fractures caused by low-energy 
trauma. Radiologists call this same sign osteopenia.
At the end of the twentieth century, the concept of 
osteoporosis changed progressively from the definition 
of a very specific disease, made by Albright in 1941, to 
the current concept of a skeletal disorder encompassing 
many pathological conditions, in which the microarchi-
tecture of the bone tissue is deteriorating(2,3). Both the 
cortical and the spongy bone tissue are affected. The 
bone microarchitecture may also become modified. The 
bone mineral density decreases. This leads to impair-
ment of bone resistance to low-energy trauma(4). Bones 
become fragile, with a predisposition towards increased 
occurrence of fractures. The high incidence of these 
fractures, called osteoporotic fractures, is the factor that 
gives importance to studies on osteoporosis.
Osteoporosis plays a part not only in increasing the 
frequency of fractures, but also in increasing the pos-
sibilities of different formats, going from fractures with-
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out clinical manifestation, such as so-called morphomet-
ric fractures of the vertebral body, and passing through 
partial fractures to highly unstable comminuted fractures 
in which anatomical reassembly of the bone is techni-
cally impossible. Some fractures may not be detectable; 
others, such as vertebral body fractures, may leave very 
painful sequelae; and still others may cause the patient’s 
death or lead to permanent physical disability, such as 
fractures of the proximal extremity of the femur.
The absolute and relative increases in the size of the 
elderly population and the unhealthy habits of children 
and adolescents are leading to very large increases in the 
incidence of osteoporosis and osteoporotic fractures.
There are many causes for the appearance and/or 
development of osteoporosis. It is called primary os-
teoporosis when the causes are natural (menopause and 
senility). It is called secondary osteoporosis when there 
is another, primary cause (certain medications, other dis-
eases, sedentarism, etc.). When the causes are unknown, 
it is called idiopathic osteoporosis.
DIAGNOSIS
It is said that osteoporosis without current fractures 
or without microfractures is a silent disease because 
it does not have specific symptoms that could lead to 
suspicion of the disease. However, this does not seem 
to be true. All diseases mediated by osteoclasts are pain-
ful. Osteoporosis is perhaps less painful, or perhaps the 
pain may go unnoticed because it is milder. Many cases 
of low back pain and other back pain may be of osteo-
porotic origin, and orthopedists need to be alert to this 
possibility. Osteoporosis also does not have any pathog-
nomonic clinical signs. Increased thoracic kyphosis and 
height loss are perhaps the most suspicious signs.
Because of the multifactorial nature of osteoporosis, 
its syndromic nature and its low clinical manifestations, 
it is difficult to diagnose. It is mostly diagnosed by or-
thopedists because of its most deleterious consequence: 
osteoporotic fracture.
Physicians must therefore remain alert with regard 
to diagnosing the risk that an individual might have os-
teoporosis. Attempts to diagnose and treat osteoporosis 
early on, before the first fracture occurs, have led to 
studying the risk factors for osteoporosis(5).
Risk factors for osteoporosis
It is necessary to distinguish between risk factors for 
osteoporosis and risk factors for osteoporotic fractures. In 
the former, the possibility that the patient might present 
osteoporosis is assessed, along with the need to perform 
subsidiary examinations to prove this. In the latter, the 
possibility that the patient might suffer fractures because 
of bone fragility is assessed, and the existence of osteo-
porosis is thus one of the risk factors.
The risk factors of greatest value for determining 
whether osteoporosis is present are female gender, white 
or oriental ethnicity, older age, early inset of the meno-
pause, heredity (presence of osteoporosis or osteoporotic 
fractures among direct-line ancestors or other relatives), 
previous history of osteoporotic fractures, nutritional er-
rors (low calcium intake, low vitamin D3 intake or low 
exposure to sunlight for production of vitamin D3, situ-
ations of poor food absorption, etc.), bad habits (exces-
sive intake of coffee, alcohol or tobacco), sedentarism, 
certain medications (glucocorticoids or anticonvulsants) 
and diseases such as rheumatoid arthritis and almost all 
systemic inflammatory diseases.
Although the risk factors for osteoporosis have been 
well known for a long time, there is still no scientific nu-
merical formula for evaluating these factors separately 
and within the general context. Moreover, it is possible 
that there may never be such a formula. Depending on 
the population studied, these risk factors have different 
relative values.
The development of densitometers has helped in the 
diagnosis, but the questions of when to perform densi-
tometry and when to repeat the assessment then arise. 
Thus, it is again necessary to evaluate the risk factors 
for osteoporosis.
Table 1 – Relative values of risk factors for osteoporosis
Coefficient Value = 1
Twice the 
value
Four times the 
value
Eight times 
the value
Absolute 
value
Gender Male Female
Ethnicity Black Mixed White Oriental
Age 20 50 60 70 80
BMI > 30 27 to 30 24 to 27 20 to 24
Age at 
menopause
> 52 48 to 52 44 to 48 Up to 44
Previous 
osteoporotic 
fracture
Any osteoporotic 
fracture
Vertebra Femur
Osteoporotic 
fracture in parents
Others Vertebra Femur
Habits Tobacco Alcohol Coffee
Physical activity Daily Frequently Occasionally Sedentary
Questions on 
different body 
systems
Anticonvulsants
Rheumatoid 
arthritis
Corticoid 
therapy
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Table 1 presents the risk factors for osteoporosis and 
their value, relative to others, as published in various 
sources of information. The column “Value = 1” is the 
basis for the calculations. Thus, individuals with female 
gender are four times as likely to present osteoporo-
sis, in relation to male gender, and those with Oriental 
ethnicity are twice as likely to present it, in relation to 
whites (8/4 = 2), and four times as likely, in relation 
to blacks (4/1 = 4). Consideration of the various fac-
tors may leads to requesting a densitometric evaluation. 
However, summing the “scores” does not produce any 
practical result. For example, the presence of any of the 
factors in the last column on the right side requires a 
bone densitometry test. Clinical experience, regarding 
this disease or any other, leads physicians to suspect that 
the disease may be present and look for a diagnosis. In 
the case of osteoporosis, the suspicion arises from the 
existence of risk factors.
Densitometry
Densitometers are devices that generate a double 
band of X-rays that crosses a region of the patient’s 
body. The radiation emitted is gathered in a collimator 
and the quantity of calcium is evaluated according to 
the area measured. The results obtained are analyzed 
in a computer and compared with a database of indi-
viduals of the same ethnicity, weight, height and age 
(20 to 100 years). The results are presented in grams/
cm2 and compared with the mean for individuals aged 
20 years (T score), which represents the peak value for 
bone mass. The mean bone mineral density values are 
also compared between individuals of the same age (Z 
scores). The relative percentages and standard devia-
tions (SDs) of the means are calculated. In accordance 
with the WHO consensus, the results are considered to 
be normal when the densitometry shows down to –1 
SD in the T score; osteopenia, from –1 to –2.5 SDs and 
osteoporosis, from –2.5 SDs downwards. Osteoporosis 
is also deemed to be present when, in addition to SD < 
–2.5, the patient presents an osteoporotic fracture. Today, 
any patient with an osteoporotic fracture is considered to 
present osteoporosis. Z scores less than or equal to –2 
are suggestive of possible secondary osteoporosis.
Like any subsidiary examination, densitometry 
should be performed when there are sufficient indica-
tions of the possibility that the patient has the disease. 
Suspicion is aroused through the existence of risk fac-
tors for osteoporosis. In the absence of risk factors, the 
rule is to firstly make densitometric evaluations on all 
individuals over the age of 65 years and on all women 
aged 50 years and over who reached the menopause at 
an early age. The examination should be repeated every 
one to three years, depending on clinical criteria, or for 
checking on treatment.
Risk factors for osteoporotic fractures
The risk factors for osteoporotic fractures are the 
same risk factors as for osteoporosis, with the addition 
of the densitometry results. Risk factors for falls are also 
important, but it must be borne in mind that ordinary 
low-energy trauma does not cause fractures in healthy 
individuals. The concept of osteoporotic fracture is that 
this is “a simple or complex fracture that occurs in in-
dividuals with apparent or non-apparent osteoporosis, 
caused by high-energy trauma”.
There is no confirmed relationship between occur-
rences of fractures and the densitometry result. Densi-
tometry measures the calcified bone mass, but it does not 
measure the quality of this bone mass. One well-known 
case is the increased bone mineral density seen from 
densitometry that results from use of sodium fluoride, 
which was greatly used in the past for treating radiologi-
cal osteoporosis, but was found to promote greater bone 
fragility. Another example is given by strontium, in the 
form of strontium ranelate, which is a promising means 
for treating osteoporosis. Because of its greater atomic 
mass and atomic radius, it produces higher bone mineral 
density readings from densitometry through greater at-
tenuation of the X-ray beam from the densitometer.
Patients who are classified as presenting “densitometric 
osteoporosis” certainly have higher incidence of fractures 
than do other individuals, and this rate is inversely propor-
tional to bone mineral density. However, the number of 
osteoporotic fractures is much greater among individuals 
who are classified as having “densitometric osteopenia”. 
Even “densitometric normal” individuals suffer osteo-
porotic fractures in large numbers. This occurs because 
the “normal” and “osteopenic” populations are larger than 
the osteoporotic population(6).
One serious public health problem is therefore how 
to identify individuals who do not present densitometric 
osteoporosis but are susceptible to osteoporotic frac-
turing. Currently, an epidemiological index named the 
FRAX (Fracture Assessment Tool) index is being stud-
ied under sponsorship from WHO(7). This makes statisti-
cal evaluations on risk factors presented by individuals 
and provides the percentage likelihood that these indi-
viduals might suffer an osteoporotic fracture over the 
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next ten years(8). In Brazil, there are already studies in 
progress aimed at establishing the FRAX index for the 
Brazilian population.
In placebo-controlled clinical studies on patients 
treated with oral bisphosphonates, losses of densito-
metric bone mass in the placebo group are accompanied 
by increased incidence of fractures, while gains in den-
sitometric bone mass of up to 5% are accompanied by 
proportional diminution of this incidence. Above 5%, 
the diminution of the prevalence of fractures continues, 
but does not maintain proportionality with the gains in 
densitometric bone mass(9).
TREATMENT
Once a diagnosis of osteoporosis has been estab-
lished and the risk of osteoporotic fractures has also 
been established, it needs to be decided whether the 
treatment should prophylactic and/or curative. Many 
interventions serve both purposes. It is obvious that 
when osteoporosis is prevented or treated, prevention 
of osteoporotic fractures is also provided.
Before discussing treatments, a brief review of BONE 
REMODELING is useful.
Bone is a type of living tissue that constantly under-
goes an exchange process from old to new tissue. The 
mediators in this process are osteocytes. From time to 
time (around every thousand days), osteocytes undergo 
apoptosis, i.e. programmed cell death. Close to the time 
of apoptosis, they produce signals for pluripotent mes-
enchymal cells to form osteoblasts.
A similar stimulus occurs when the bone is subject-
ed to physical effort for which it is unprepared. Either 
through pressure on the cell membrane proteins(10), or 
through stimulation of primary cilia (the organelles 
of osteocytes that detect these tensions), signals are 
sent to the mesenchymal cells, to trigger osteoblast 
formation.
Osteoblasts produce the RANK (Receptor Activator 
of Nuclear factor Kappa beta) factor, which signals to 
hematopoietic cells for them to form osteoclasts, and 
also activates the brush border of these osteoclasts.
Over a 20-day period, the osteoclasts reabsorb some 
of the bone tissue, thus forming Howship’s lacunae. 
Osteoblasts then fill these lacunae with protein matrix 
and lastly, deposit hydroxyapatite crystals in them. This 
process takes 180 days to complete.
If this remodeling process is disturbed, through 
greater proportional action of osteoclasts in relation to 
osteoblasts, the bone tissue formation will be impover-
ished. Depending on the severity of the situation, this 
may give rise to osteopenia or to osteoporosis.
Thus, in preventing or treating osteoporosis, osteo-
clast activity needs to be decreased or osteoblast activity 
needs to be increased, or both of these.
The ideal would seem to be to stimulate bone forma-
tion by stimulating the action of osteocytes or osteo-
blasts. However, while stimulation of osteoclasts pro-
duces action within 20 days, the osteoblasts will take 
180 days to repair the lacunae left by the osteoclasts. 
This explains why certain anabolic treatments, i.e. treat-
ments that stimulate osteoblasts, do not always achieve 
the expected results.
The following are anabolic treatments: physical ac-
tivity, calcitriol (vitamin D), associations between cal-
cium and calcitriol, anabolic steroids, growth hormones, 
parathormone (PTH) and its derivative teriparatide, and 
strontium ranelate.
The following are anticatabolic treatments, i.e. treat-
ments that inhibit the action of osteoclasts: physical 
activity, associations between calcium and calcitriol, 
active metabolites of calcitriol, estrogen replacement 
therapy, hormone replacement therapy (HRT), SERMs 
(selective estrogen receptor modulators), bisphospho-
nates, osteoprotegerin (OPG) and strontium ranelate.
Physical activity
This is the cheapest means of prevention and coad-
juvant for treatments. Exercises with weights and speed 
exercises are the most effective ways of gaining bone 
mass. In addition, the gain in muscle mass and improve-
ment in the speed of the neuromuscular motor response 
diminish the numbers of falls and the risk of fractures 
among patients. The piezoelectric effect of physical ac-
tivity, or the action of the primary cilia, stimulates the 
osteocytes (via osteoblasts) to promote the formation 
of new bone.
Comparison between elderly people who practice 
physical activity and sedentary elderly people shows 
that the incidence of hip fractures among active indi-
viduals is lower(11).
Calcium supplementation
Calcium forms part of the hydroxyapatite crystal 
(Ca10(PO4)6(OH)2), which gives mechanical resistan-
ce to bone tissue. In the composition of bone tissue, 
this crystal corresponds to 65%. Calcium also plays a 
part in blood coagulation, metabolic regulation through 
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metalloenzymes (alpha-amylase, phospholipases, etc), 
hormone and neurotransmitter secretion and cell adhe-
sion. Because of the presence of calcium in the troponin 
molecule, which regulates the contractility of actin and 
myosin, it participates in muscle contraction, including 
in the heart. The importance of this action means that, 
biologically, calcemia levels need to remain as constant 
as possible.
In nature, calcium is present in all living organisms. 
The greatest sources are milk and dairy products. Sar-
dines, beans and vegetables with dark leaves are also 
very rich in calcium. However, it is not always the case 
that consumption of foods rich in calcium results in 
absorption of calcium in the intestine. This absorption 
depends on whether the calcium is in the form of absor-
bable salts. Thus, the presence of oxalic acid, vitamin 
C, phytates (present in cooked greens), certain fibers, 
proteins and even lactose may cause the formation of 
insoluble or non-absorbable compounds.
Another source of calcium is the exoskeleton of 
mollusks. From this, calcium carbonate is extracted, 
which is soluble and absorbable in acid pH. Because of 
this chemical characteristic, calcium carbonate is poorly 
absorbed in elderly people (because of hypochlorhydria) 
and in patients who take antacids, etc. In these situations 
and in cases of nephrolithiasis, calcium citrate is used 
because it is more absorbable and acidifies urine. Cal-
cium orthophosphate is used in cases of elderly people 
with low phosphorus intake (rare) who are institutiona-
lized and have difficulties in feeding themselves.
In the intestine, calcium is absorbed via paracellular 
and transcellular pathways. The paracellular pathway 
is passive and depends on the quantity of calcium in 
the food bolus, the speed of digestion and the pH of the 
chyle and calcium salt, along with the presence of other 
products already cited above. The transcellular pathway 
is active and depends on the presence of calbindin, whi-
ch is synthesized by vitamin D.
All the calcium present in the blood is filtered by 
the renal glomeruli and most of it is reabsorbed by the 
tubules. Some of it is eliminated (100 to 300 mg per 
day) through the urine and needs to be replaced.
Among individuals over the age of 50 years, with 
or without HRT, it is essential to supplement the diet 
every day with up to 1500 mg of calcium, taken as two 
doses. A non-dairy daily diet has up to 700 mg and a 
diet rich in dairy products has up to 950 mg. Additional 
calcium is provided so that the organism can make use 
of what it requires.
The pharmaceutical products are named in accor-
dance with the quantity of elemental calcium that the 
tablets or sachets contain and not the quantity of the 
salt. Thus, 1250 mg of calcium carbonate appears as 
“calcium 500”.
Administration of calcium alone is efficient for di-
minishing the incidence of fractures(11).
Vitamin D
Vitamin D is a “quasi hormone”. It acts on the in-
testinal absorption of dietary calcium and on reabsorp-
tion of urinary calcium in the renal tubules. It reduces 
the levels of PTH and stimulates osteogenesis by the 
osteoblasts. It has antibiotic action on the respiratory 
tree. It acts to modulate the equilibrium of the CNS. 
It facilitates increases in muscle strength, particularly 
in cases of sarcopenia. It stimulates cell differentiation 
and inhibits cell proliferation, thus acting as a protector 
against breast, prostate and intestinal cancer. The need 
for vitamin D increases with age(12). It is produced na-
turally through the action of UVB rays in sunlight on 
the 7-dihydrocholesterol circulating under the irradia-
ted skin, thereby transforming it into cholecalciferol. 
This molecule, which already contains one hydroxyl 
group, receives another one on its carbon 25 when it 
passes through the liver, thus forming calcidiol or 25-
hydroxycholecalciferol. A third hydroxyl is attached 
to its carbon 1 in the kidneys, thus forming calcitriol 
or 1,25-dihydroxycholecalciferol. Cholecalciferol or 
vitamin D3 exists in the liver of cold-water fish, in eggs 
and in enriched milk. There is little in human milk. 
Its isomer ergosterol, or vitamin D2, exists in plants. 
Vitamins D3 and D2 and calcidiol are inactive. Cal-
cidiol is the depot form. Calcitriol and its metabolite 
alfacalcidol are the active forms regarding absorption 
of calcium from the intestinal lumen and reabsorption 
of urinary calcium in the renal tubules. They have a 
very short life and, for this reason, they are not assayed. 
Calcidiol can be assayed and should be maintained 
between 32 and 100 ng/ml of serum(13). It is requested 
from laboratories as serum “25-OH-vitamin D”. To 
maintain this level, the ideal intake is 800 to 1200 IU 
of vitamin D3 per day.
Several formulations are available on the market. 
When associated with calcium, the concentration is ge-
nerally 200 IU/tablet. Other preparations exist, consis-
ting of associations of cholecalciferol with retinyl pal-
mitate (vitamin A) and with alpha-tocopherol (vitamin 
E). For example, Ad-til contains 250 IU of vitamin D 
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and 1250 IU of vitamin A per drop (40 drops/ml). Forty 
drops per day is used to restore the ideal concentration 
in the serum (for around three months), and 40 drops 
per week to maintain it.
The association of calcium and D is efficient for di-
minishing the incidence of fractures(14).
Anabolic steroids and growth hormones
These act to improve the formation of protein matrix 
and stimulate osteoblasts. Because of their adverse ef-
fects, they are little used. In cases of secondary osteopo-
rosis due to male hypogonadism, urologists frequently 
use methyl testosterone with efficient results.
Teriparatide and PTH
Parathormone is formed by 84 amino acids arranged 
in a linear chain. Teriparatide is its homologue, with 
amino acids 1 to 34 only, obtained by means of the re-
combinant DNA technique. Together, when administered 
continuously, they increase the binding of RANK to pre-
osteoclasts, thereby stimulating replication of the latter, 
and to osteoclasts, thereby stimulating their bone tissue 
reabsorption action. Thus, PTH and teriparatide have 
great capacity for bone reabsorption (cystic fibrous os-
teitis). However, when used daily in small doses, they 
inhibit the RANK system and increase OPG levels, 
thus inhibiting bone reabsorption. In this case, they also 
stimulate the replication and activity of endosteal and 
periosteal osteoblasts. Through this, they increase the 
thickness of the cortical bone, the cross-sectional area 
of the bone and the thickness and connection of the 
trabeculae(15). This gives greater mechanical resistance 
to the bone(16). They are used in the form of daily sub-
cutaneous microinjections, by means of a “pen” with 
28 doses. This treatment is often indicated for patients 
who are at high risk of fractures and/or refracturing(17). 
Currently, many studies seeking to associate teriparatide 
use concomitantly or sequentially with anti-reabsorptive 
agents are being developed(18-20).
Hormone replacement therapy (HRT) and 
estrogen replacement therapy
These are efficient for preventing postmenopausal 
osteoporosis, but not for treating it. They should be 
started soon after the menopause, under supervision by 
a gynecologist because of their potential adverse effects. 
The greatest problem is the increase in occurrences of 
breast cancer, along with thromboembolic disorders.
SERMs
SERMs or selective estrogen receptor modulators 
are used when patients are at an increased risk of breast 
cancer. They inhibit estrogen receptors in the breasts 
and uterus, thus protecting these two organs against the 
deleterious action of estrogen. The type of SERM most 
used is tamoxifen.
Other SERMs have been developed as substitutes 
for HRT, for preventing and treatment of osteoporosis, 
with estrogen-stimulating action on the estrogen recep-
tors of bones, the cardiovascular system and lipids. 
Thus, they prevent and treat osteoporosis, prevent hy-
percholesterolemia and vascular atheromatous plaque, 
and do not stimulate the development of breast and 
uterine cancer. Raloxifen hydrochloride and lasofox-
ifene are examples. 
Bisphosphonates
Bisphosphonates (or geminal bisphosphonates) are 
polyphosphates that have at least one P-C-P connection 
(phosphorus – carbon – phosphorus) in the molecule. 
They were first synthesized by Menschutkin in 1865, 
for use as industrial anticorrosive agents. Subsequently, 
they started to be used as softeners for “hard water” (al-
kaline water) in laundries, and in water pipes (to impede 
the deposition of calcium carbonate).
In 1968, Fleish and Russel discovered pyrophosphate 
in plasma and urine and, in 1970, they discovered that it 
inhibited precipitation of calcium carbonate in the uri-
nary vessels and passages, thus constituting a biological 
“softener”. Because etidronate had been in clinical use 
for treating bone metabolism diseases since 1968, they 
started to investigate the use of bisphosphonates to treat 
osteoporosis and Paget’s bone disease.
The bisphosphonate molecule is formed by a cen-
tral carbon atom to which two phosphate radicals, one 
R1 radical (ideally a hydroxyl group) and one R2 radi-
cal (ideally containing a cyclic chain and a nitrogen 
atom) are bonded. Depending on the spatial formation 
of this molecule, it will have greater or lesser capacity 
for adsorption on hydroxyapatite molecules. It is known 
that the P-C-P chain with a hydroxyl group on each 
of these atoms is the best formation for adsorption on 
hydroxyapatite.
This adsorption is important because when osteo-
clasts reabsorb bone tissue, they also absorb bisphos-
phonates. Inside the cytoplasm of phagocytes, aminated 
bisphosphonates (i.e. with nitrogen in the R2 radical) 
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act on mevalonate to inhibit an enzyme called farnesyl 
pyrophosphate synthase (FPPS). This enzyme promotes 
the transformation of geranyl pyrophosphate into gera-
nyl-geranyl pyrophosphate and farnesyl pyrophosphate. 
These metabolites promote prenylation of the small pro-
teins that are essential for the brush border to function 
and for osteoclasts to survive. Thus, by breaking the 
mevalonate chain, the bone absorptive function of os-
teoclasts is inhibited.
The bisphosphonates that can be used in osteoporosis 
therapy are differentiated according to their capacity for 
adsorption of hydroxyapatite crystals and their power to 
inhibit osteoclast function.
The following bisphosphonates have been registered 
in Brazil for treating osteoporosis: sodium alendronate, 
sodium pamidronate, sodium risedronate, sodium iban-
dronate and zoledronic acid. Comparison of antiresorp-
tive power in relation to etidronate (taken to have a 
value of one) shows that alendronate is 1,000 times 
more powerful, risedronate 5,000 times and zoledronic 
acid 10,000 times. Regarding the adsorptive capacity, 
the adsorption affinity constant for etidronate is 1.2; 
risedronate, 2.2; ibandronate, 2.3; ibandronate, 2.9; and 
zoledronic acid, 3.4(21).
Bisphosphonates for oral use have low solubility and, 
for this reason, should be administered while fasting, 
with a glass of pure water (mineral water is not recom-
mended). Patients should continue to fast for another 
half hour. Since these substances are aggressive to the 
esophageal mucosa, patients should lie down during this 
first half hour, while the stomach is still emptying, so 
that esophageal reflux is avoided.
Only 1% is absorbed (0.6% for ibandronate). Of this, 
51% is eliminated via the kidneys, without metaboliza-
tion, while 49% is adsorbed in the hydroxyapatite, par-
ticularly in new bone material. When bisphosphonates 
are released into the bloodstream through the death of 
osteoclasts or through “de-adsorption”, they are again 
adsorbed into hydroxyapatite. Some types, such as rise-
dronate, have greater “de-adsorption”, which explains 
their better distribution throughout the bone tissue and 
their multi-site effect.
It is likely that these known differences, and others 
that remain unknown, cause the differences in the anti-
fracture actions of different bisphosphonates. Whereas 
they are similar in the way they act, they differ in their 
power of action. Thus, they act differently in relation to 
remission of densitometric osteoporosis and diminution 
of the prevalence of fractures.
It seems that the best quality of alendronate is the 
clinical experience of its use that has been accumulated. 
Since this was the first effective drug against osteopo-
rosis, it has been in use for the longest time and by the 
greatest number of individuals. Its greatest problem is 
that many similar drugs exist: these have not been tested 
clinically but are frequently prescribed as substitutes for 
the original salt. Another problem is the current suspi-
cion that fractures can be caused through strong inhibi-
tion of bone modeling (frozen bone), when this drug is 
used for a long time. Alendronate has been tested at a 
dose de 10 mg per day, orally. A bridge study has shown 
that a dose of 70 mg per week is also efficient for inhib-
iting the incidence of osteoporotic fractures. A presenta-
tion consisting of 70 mg and 2,800 IU of vitamin D3 for 
weekly use was recently launched, and one with 5,600 
IU, also for weekly use, is to be launched.
Risedronate is the drug that has been used for the 
second longest time, with the second largest population 
of users. Its best quality is its proven rapidity of action 
and its multi-site efficacy of anti-fracture action, particu-
larly with regard to hip fractures, as demonstrated in a 
specific clinical study, the Hip study(22). It was originally 
tested and launched at a dose of 5 mg per day for oral 
use. A bridge study demonstrated that it was effective 
at a weekly does of 35 mg, and a new bridge study has 
now demonstrated that monthly use at a dose of 150 
mg is valid(23).
The best quality of ibandronate is its formulation of 
150 mg, for oral use once a month. It has now been shown 
that oral bisphosphonates can be administered in larger 
doses at longer intervals, while maintaining their effect 
as seen through densitometric evaluations. Originally, it 
was launched as doses of 2.5 mg for oral use, daily.
Zoledronic acid differs from the other drugs men-
tioned above because it is for intravenous use, as an 
annual dose. This drug too has been studied specifi-
cally for patients with hip fractures, in the Horizon RFT 
study(24), which showed that there was lower incidence 
of recurrent fractures in the active drug group, and that 
the treated group had longer survival than the placebo 
group. For this reason, and because of the advantage that 
it can be used for bedridden patients, it is often indicated 
for use among patients who have recently undergone op-
erations to treat fractures of the proximal femur. It also 
has the advantage of adherence to treatment, because 
of the annual dosage. Currently, it is registered only for 
treatment, but the manufacturer is awaiting authorization 
for its additional use, for prevention of osteoporosis.
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The percentage diminution of fracture incidence 
and the percentage remission of densitometric condi-
tions achieved by different bisphosphonates and other 
therapies cannot be compared because the populations 
studied in different investigations were very different 
from each other. There are still not enough comparative 
head-to-head (drug versus drug) studies to establish any 
great differences between the treatments(25).
Osteoprotegerin
Osteoprotegerin is a product that is coming onto the 
market now, after several years of research. It acts by 
inhibiting RANK, thereby impeding it from binding to 
osteoclasts and thus stimulating the latter to reproduce 
and activate its brush border.
Strontium ranelate
Strontium ranelate is a product for treating osteopo-
rosis that presents two actions: it is anti-reabsorptive 
and, at the same time, it is pro-formative(26).
It is a salt of ranelic acid with two strontium atoms in 
each molecule. It is absorbed in the intestine, and vitamin 
D does not have any effect on this absorption. Ranelic 
acid is not metabolized, has little bonding to plasma pro-
teins, does not accumulate in the human organism and is 
rapidly eliminated through the kidneys, thereby leaving 
the two strontium atoms free to be adsorbed into hy-
droxyapatite (small quantities replace the calcium atoms 
in the composition of the crystal)(27).
The bioavailability of strontium, administered as 2.632 
g of hydrated strontium ranelate (2 g of the anhydrous 
form), is 27%(28). The maximum serum concentration 
of strontium is reached in three to five hours. The half-
life is 62 hours and the proportion that is not adsorbed 
into the hydroxyapatite is excreted through the kidneys 
(57%) and intestine. Strontium does not bind to plasma 
proteins, it is not metabolized and it does not inhibit the 
P450 cytochrome system. It reaches an equilibrium point 
after two weeks, and the half-life is 10 weeks.
Strontium is a chemical element that is very similar to 
calcium and magnesium. Its valence is +2 (like calcium 
and magnesium); it has 38 electrons distributed in four 
layers (calcium has 20 in three layers); its atomic radius 
is 215 (for calcium, it is 197); and its ionic radius is 
116 (for calcium, it is 100). These similarities cause the 
organism to confound them, in relation both to intestinal 
absorption and to participation in hydroxyapatite crys-
tals. The absorption depends on the salt (ranelic acid was 
developed for this reason), the dose (in this case, 2 g), 
the presence of calcium in the diet (administered in the 
evening, three hours after dinner), renal function and 
the animal species that is studied.
Since strontium diminishes the activity of vitamin D3 
hydroxylase, its excess may lead the bone to osteomala-
cia. At the recommended small doses, it stimulates nor-
mal calcification of the osteoid tissue.
In bone tissue cultures, it stimulates replication of 
pre-osteoblasts, thereby increasing the numbers of os-
teoblasts and thus increasing bone formation. It also 
stimulates the formation collagen.
On the other hand, it reduces the differentiation of 
osteoclasts and reduces their activity. For this reason, it 
inhibits bone reabsorption. It is therefore pro-formative 
and anti-reabsorptive.
There are increases in the bone formation markers 
(alkaline phosphatase and pro-peptide C), while there 
are decreases in the bone reabsorption markers (serum 
C-telopeptide and urinary N-telopeptide), as early as the 
third month, thus confirming its double action.
In animal tissue and human biopsies, it has been 
shown that it improves the bone microarchitecture(29,30). 
It acts by stimulating the trabecular volume, thereby 
increasing the number of trabeculae and their thickness. 
It does not impair bone quality and mineralization, and 
thus it does not leave mineral defects.
In addition to formation of endosteal bone, it stimu-
lates the production of periosteal bone, which improves 
the macroarchitecture and resistance of the bone(30).
More recent studies using state-of-the-art technology 
such as high-resolution peripheral quantitative computed 
tomography (HR-pQCT) have suggested that strontium 
ranelate acts more rapidly and more effectively towards 
formation of new cortical and trabecular bone than does 
alendronate(31). This would suggest that it is more effec-
tive in preventing fractures.
The presence of strontium in the bone increases the 
absorption of X-rays, as seen in densitometry. A recently 
published comparative study stated that, for strontium 
ranelate, bone mineral density measurements report at 
least 75% efficacy against fractures, while for bisphos-
phonates, this estimate is between 4% and 28%(32).
The Soti and Tropos studies,(33,34) over a period of up 
to five years, proved the efficacy of strontium ranelate 
in patients with osteoporosis, from the initial stages to 
more advanced stages, including among populations of 
patients aged 80 years and over. These studies proved 
that the risk of vertebral fractures was reduced by 45% 
and the risk of hip fractures was reduced by 43%, both 
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in patients without previous fractures (45%) and in pa-
tients with fractures (41%).
Choice of treatment
The ideal treatment would be one that diminished 
the incidence of fractures through improving the bone 
geometry and its microarchitecture. The recently formed 
bone tissue should be of good cell and matrix quality 
and present normal mineralization with good propor-
tions between mineralized bone (mechanically resistant) 
and unmineralized bone (flexible), without accumulation 
of damage. The ideal treatment should have a positive 
remodeling rate and a rapid and long-lasting therapeutic 
effect. This effect should be easily detectable. The treat-
ment should be safe.
However, this ideal treatment still does not exist. 
The various treatments cited above each present some 
of these ideal characteristics and do not present others. 
The choice of treatment for each patient depends on the 
patient’s characteristics, the severity of the pathological 
condition and the physician’s knowledge of the thera-
peutic arsenal as a whole and of the medication that will 
be prescribed in particular.
The problem of the cost of the treatment will always 
be present, especially with regard to avoiding abandon-
ment of the treatment. Physicians (and society) have 
the duty to pressure the public authorities to allow the 
use of the best treatments that their conscience and 
knowledge indicate.
It is preferable to use a medication for which the phy-
sician has good knowledge of the indications, adverse 
effects, interactions with other drugs and contraindica-
tions in relation to other pathological conditions pre-
sented by the patient.
Organic molecules present spatial isomers that are 
chemically equal but may not be biologically equal. 
Cheaper similar and generic drugs may even be more 
effective than the branded products, but may not have 
been tested in accordance with the rigorous requirements 
of the registration agencies. In relation to a long-term 
disease that affects elderly patients, there is no time to 
waste on experiments with cheaper products.
Some indications are formal: the use of teriparatide 
for patients at high risk of osteoporotic fracture; the use 
of risedronate when fast multisite action is required, 
especially in order to prevent hip fractures; the use of 
zoledronic acid when adherence to treatment for at least 
one year is required; the use of bisphosphonates when the 
patient is bedridden; the use of zoledronic acid for bedrid-
den patients following operations to treat hip fractures; 
and the use of teriparatide and strontium ranelate when 
reactivation of bone metabolism that seems to be “fro-
zen” through prolonged use of alendronate is required.
It is obvious that in cases of secondary osteoporosis, 
it is important to treat the primary cause. Nonetheless, in 
all cases of osteoporosis, whether primary or secondary, 
patients may benefit from any of the above treatments.
FINAL REMARKS
Assessment of treatment efficacy
The ideal assessment would consist of mechanical re-
sistance tests in association with anatomopathological or 
histomorphometric examinations on the treated bones. 
Decreased incidence of vertebral and non-vertebral os-
teoporotic fractures, including at the proximal extremity 
of the femur, would also be good ways of evaluating 
this. The problem is the practicality of these evaluations. 
Thus, the fallback method is to assess the reduction of 
the relative risk (RR) of occurrence of an osteoporo-
tic fracture, which has been established by statisticians 
based on clinical and laboratory studies.
There is controversy regarding the extent to which 
each drug reduces the relative risk of each fracture in 
each population in particular. However, there is no con-
troversy regarding orthopedists’ moral (and legal) obli-
gation to treat patients with osteoporotic fractures or to 
refer them for treatment.
The best evaluation method continues to be densi-
tometry. Results over periods of less than one year are 
inconclusive and, for this reason, the first evaluation 
should be made after one year of treatment, except 
in cases of osteoporosis induced by glucocorticoids 
(which should be done every six months). When the 
annual densitometry evaluation shows a gain in bone 
mass greater than 2%, evaluations can then be under-
taken every two years.
Vertebral quantitative computed microtomography 
provides images of the trabecular bone, from which the 
efficacy of the treatment can be inferred. This is not used 
in daily clinical practice because it is performed in a 
piece of equipment that is still very expensive. However, 
it is increasingly used in research.
Biochemical markers for bone turnover are of great 
interest for clinical research or, in cases of doubt regard-
ing treatment efficacy, for very short-term clinical evalu-
ations. Serum markers for bone formation and markers 
for bone reabsorption (which are generally urinary) may 
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provide information after only three months of treat-
ment. The bone formation markers most commonly 
evaluated are total serum alkaline phosphatase and its 
bone fraction, osteocalcin and serum type I carboxyl 
and amino-terminal pro-collagen peptides (serum C and 
N pro-peptides). The bone reabsorption markers most 
commonly evaluated are urinary hydroxyproline, serum 
and urinary N (NTx) and C (CTx) telopeptides, urinary 
pyridinoline and deoxypyrinoline (DPD), serum tartrate-
resistant acid phosphatase and calciuria.  
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